Treatment principle 89SrCl2 injection is a kind of analgesic treatment drug produced by the reactor for direct intravenous injection, which has remarkable efficacy for severe pain caused by bone metastases from many kinds of advanced cancers. Strontium 89 is a calcium group element, a kind of osteophilic radionuclide, which enters the body and participates in the metabolic process of bone minerals like calcium. After intravenous administration, the uptake rate in malignant tumor bone metastasis lesions is greater than that of normal bone tissue by 2 to 25 times, and stays in the cancer foci, emitting beta rays with an average energy of 1.463 MeV and a half-life of 50.5 days, and its radiation effect kills cancer cells, shrinks the lesions and acts as a good analgesic. Its radiation effect kills cancer cells, shrinks lesions and plays a good analgesic role. Indications Patients with advanced stage of prostate cancer, breast cancer, lung cancer, etc., tumor cells will metastasize to the whole body skeletal system, causing severe bone pain to patients. The tumor infiltrates into the nerve-rich periosteum and causes severe bone pain through mechanical compression of the tumor and secretion of various pain-causing substances, etc., which seriously affects the quality of life and requires the use of analgesic drugs, with the disadvantages of clinically used morphine-based analgesics such as large side effects, strong addiction and poor tolerability. After strontium-89 treatment, most patients have very significant pain relief effect, and get obvious pain relief effect about 10 days after injection, and more than half of them have complete pain relief, and can maintain for 3-6 months, improving the quality of survival. Treatment effect Strontium-89 treatment is very easy, it can be directly pushed intravenously after establishing intravenous access, and the general dose of the drug is 3~5 milli curies, and the treatment can be repeated for an unlimited number of times. After 10 days of intravenous injection, most of the patients have obvious analgesic effect, and more than half of them are completely relieved of pain; some of the patients can find that the bone metastases are reduced or disappeared, and the effective rate is more than 80%, and the pain treatment can be valid for 4-6 months. Because strontium-89 is a pure beta nuclide, it poses minimal radiation hazard to the surrounding environment and family members, and has no significant effect on the bone marrow hematopoietic function of patients. Preparation before treatment: (1) whole body bone imaging (2) liver function, kidney function, routine blood and urine tests (3) pathological diagnosis of the primary tumor (4) low calcium diet.